Precision Medicine and Men’s Health

Mata, Douglas A.; Katchi, Farhan M.; Ramasamy, Ranjith

doi:10.1177/1557988315595693

Cited by 9 publications

(5 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result suggests a very important role for precision medicine in the management of PCa as only a subset of patients may benefit from certain approaches. 58 Our Moffit Cancer Center-based study strongly showed that FN1 overexpression positively correlated with overall death and PCa-specific death in PCa. To our knowledge, this is the first description of FN1 as a prognostic biomarker in human clinical PCa.…”

Section: Discussionmentioning

confidence: 82%

miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin

Das¹,

Naidoo

Ilboudo

et al. 2016

Experimental Cell Research

View full text Add to dashboard Cite

Prostate cancer (PCa) is frequently diagnosed in men, and dysregulation of microRNAs is characteristic of many cancers. MicroRNA-1207-3p is encoded at the non-protein coding gene locus PVT1 on the 8q24 human chromosomal region, an established PCa susceptibility locus. However, the role of microRNA-1207-3p in PCa is unclear. We discovered that microRNA-1207-3p is significantly underexpressed in PCa cell lines in comparison to normal prostate epithelial cells. Increased expression of microRNA-1207-3p in PCa cells significantly inhibits proliferation, migration, and induces apoptosis via direct molecular targeting of FNDC1, a protein which contains a conserved protein domain of fibronectin (FN1). FNDC1, FN1, and the androgen receptor (AR) are significantly overexpressed in PCa cell lines and human PCa, and positively correlate with aggressive PCa. Prostate tumor FN1 expression in patients that experienced PCa-specific death is significantly higher than in patients that remained alive. Furthermore, FNDC1, FN1 and AR are concomitantly overexpressed in metastatic PCa. Consequently, these studies have revealed a novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in PCa.

show abstract

Section: Discussionmentioning

confidence: 82%

miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin

Das¹,

Naidoo

Ilboudo

et al. 2016

Experimental Cell Research

View full text Add to dashboard Cite

show abstract

“…Here, we present data that suggest that miR-1207-3p could possibly contribute to the disproportionate aggressiveness of miR-1207-3p in moAA. The discovery of a miRNA biomarker that is capable of distinguishing between indolent and aggressive PCa and displays differential expression in men of different ancestry would be of great significance for the development and optimization of personalized treatment approaches [33] . Moreover, as moAA have a two-fold higher chance of getting PCa and aggressive PCa, it is of great importance to enhance our understanding of the molecular mechanisms which may explain the disproportionately increased aggressiveness of PCa in moAA [8] , [31] , [32] .…”

Section: Discussionmentioning

confidence: 99%

miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer

Das

Osborne

Lin

et al. 2016

Translational Oncology

View full text Add to dashboard Cite

MicroRNAs (miRNAs) have been found to be dysregulated in prostate cancer (PCa). In this study, we investigated if miR-1207-3p is capable of distinguishing between indolent and aggressive PCa and if it contributes to explaining the disproportionate aggressiveness of PCa in men of African ancestry (moAA). A total of 404 patients with primary adenocarcinoma of the prostate were recruited between 1988 and 2003 at the Moffitt Cancer Center, Tampa, FL, USA. Patient clinicopathological features and demographic characteristics such as race were identified. RNA samples from 404 postprostatectomy prostate tumor tissue samples were analyzed by real-time quantitative reverse transcription polymerase chain reaction for the mRNA expression of miR-1207-3p. miR-1207-3p expression in PCa that resulted in overall death or PCa-specific death is significantly higher than in PCa cases that did not. The same positive correlation holds true for other clinical characteristics such as biochemical recurrence, Gleason score, clinical stage, and prostate-specific antigen level. Furthermore, miR-1207-3p expression was significantly less in moAA in comparison to Caucasian men. We also evaluated whether miR-1207-3p is associated with clinical outcomes adjusted for age at diagnosis and tumor stage in the modeling. Using competing risk regression, the PCa patients with a high miR-1207-3p expression (≥ 6 vs 3) had a high risk to develop PCa recurrence (hazard rate = 2.5, P < .001) adjusting for age at diagnosis and tumor stage. In conclusion, miR-1207-3p is a promising novel prognostic biomarker for PCa. Furthermore, miR-1207-3p may also be important in explaining the disproportionate aggressiveness of PCa in moAA.

show abstract

“…We found rather that uncontrolled DM and uncontrolled hyperlipidemia were associ-ated with ED, while only uncontrolled hyperlipidemia was identified as an independent co-morbid negative predictor of response to Li-ESWT for Taiwanese patients with ED. Moreover, while this finding is partially incongruous with those of Vita et al, wherein age ≥ 65 years, DM, and hypercholesterolemia were associated with early non-responsiveness or reduced response to Li-ESWT [29], it is clinically relevant in terms of patient stratification for personalized medicine and effective management of ED cases in Taiwan, taking into account patients' individual variability in disease susceptibility and therapy response, while drawing out management plans [30].…”

Section: Discussionmentioning

confidence: 65%

Efficacy of Penile Low-Intensity Shockwave Therapy and Determinants of Treatment Response in Taiwanese Patients with Erectile Dysfunction

Tzou

Bamodu

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Background: Erectile dysfunction (ED) remains an emotional wrench to patients and a therapeutic challenge to urologists in andrology clinics worldwide. This is, in part, related to refraction to, or transient effect of phosphodiesterase 5 inhibitors (PDE5i), coupled with patients’ dissatisfaction with this treatment modality. Low-intensity extracorporeal shockwave therapy (Li-ESWT) is an evolving treatment option, with promising curative potential. Current international guidelines are inconclusive, bear weak recommendation strength, and lack ethnogeographic consensus. Objectives: This study evaluated the safety, efficacy, and effect duration of Li-ESWT, as well as exploring disease-associated determinants of treatment success in Taiwanese males with ED. Methods: A cohort of 69 eligible cases treated with 12 sessions of Li-ESWT and followed up for at least 12 months after treatment, between January 2018 and December 2019 at our medical facility, was used. The present single-center, retrospective, non-randomized, single-arm study employed standardized erectile function evaluation indices, namely, the five-item International Index of Erectile Function (IIEF-5) and Erection Hardness Score (EHS). Clinicopathological analyses of selected variables and comparative analyses of time-phased changes in the EF indices relative to baseline values were performed. Evaluation of treatment success was based on minimal clinically important difference (MCID), using a binomial logistic regression model. Results: The median age and duration of ED for our Taiwanese cohort were 55 years and 12 months, respectively, and an average of 31.3% presented with co-morbidities. The mean improvement in IIEF-5, EHS, and quality of life (QoL) domain scores relative to the baseline values was statistically very significant (p < 0.001) at all indicated follow-up time-points. When stratified, Taiwanese patients with severe and moderate ED benefited more from Li-ESWT, compared with those in the mild or mild-to-moderate group. Patients’ pre-Li-ESWT PDE5i response status was not found to significantly influence Li-ESWT response. Univariate analysis showed that age > 45 years (p = 0.04), uncontrolled diabetes mellitus (p = 0.04), and uncontrolled hyperlipidemia (p = 0.01) were strongly associated with Li-ESWT efficacy; however, only age > 45 years (p = 0.04) and uncontrolled hyperlipidemia (p = 0.03) were found to be independent negative predictors of Li-ESWT success by the multivariate logistic model. Follow-up was uneventful, with no treatment-related adverse events or side effects reported. Of the treated patients, 86.1% indicated satisfaction with the treatment regimen, and over 90% indicated they would recommend the same therapy to others. Conclusions: Li-ESWT is a safe and efficacious therapeutic modality for Taiwanese patients with ED. Uncontrolled hyperlipidemia and age > 45 years are independent negative predictors of treatment success for this cohort.

show abstract

Precision Medicine and Men’s Health

Cited by 9 publications

References 58 publications

miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin

miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin

miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer

Efficacy of Penile Low-Intensity Shockwave Therapy and Determinants of Treatment Response in Taiwanese Patients with Erectile Dysfunction

Contact Info

Product

Resources

About